Literature DB >> 1359322

Amphotericin versus pentamidine in antimony-unresponsive kala-azar.

M Mishra1, U K Biswas, D N Jha, A B Khan.   

Abstract

We compared the efficacy of amphotericin B and pentamidine isethionate in a prospective randomised trial in 120 uncomplicated and parasitologically confirmed cases of antimony-unresponsive kala-azar. Doses were twenty intramuscular injections of pentamidine 4 mg/kg on alternate days or fourteen definitive doses of amphotericin 0.5 mg/kg infused in 5% dextrose on alternate days. 48 (80%) patients given pentamidine showed initial cure and 46 (77%) showed definitive cure compared with 60 (100%) and 59 (98%) cases, respectively, on amphotericin (p < 0.001). Amphotericin also brought about quicker abatement of fever and more complete spleen regression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359322     DOI: 10.1016/0140-6736(92)92952-c

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major.

Authors:  Douglas R Rice; Paola Vacchina; Brianna Norris-Mullins; Miguel A Morales; Bradley D Smith
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

Review 4.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 5.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

6.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

7.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Treatment of visceral leishmaniasis.

Authors:  E M Moore; D N Lockwood
Journal:  J Glob Infect Dis       Date:  2010-05

Review 9.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

Authors:  H W Murray; J Hariprashad; R E Fichtl
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.